E Interview With Vitality Biopharma Inc.


InvestInMJ recently had the pleasure to speak with Robert Brooke, the CEO of Vitality Biopharma (“Vitality”) (OTCQB: VBIO), a publicly traded pharmaceutical company focused on cannabis based medical drugs. While researching the company and speaking to Robert, we became very excited about the prospects for the company and the potential for their drug delivery system. After reading the Q&A interview below, we are confident you will agree that they have the potential to become one of the leading pharmaceutical companies that can bring unique and effective cannabis based drugs to market. 

IMJ: Hello Robert, thank you for taking the time to speak with us. The success of any company entering the medical cannabis industry is highly dependent on management, can you provide us a brief background on the key team members and their past experiences/success in bringing a drug to market and managing a pharmaceutical company.

RB: Our board and management team has a strong track record and their careers have been focused almost entirely on healthcare, biotechnology, and drug development. I’m the company’s CEO and a Co-Founder, and am a bioengineer by training. After working in hedge fund finance for several years following graduate school at UCLA, I founded a cancer drug development company. The company, now known as Lion Biotechnologies (NASDAQ:LBIO) is developing cancer immunotherapies in collaboration with the National Cancer Institute. The hedge fund I was with previously was the single most active investor in publicly-traded biotechnology companies during a period when I was with the firm, so it was exciting and fast-paced work. We invested directly in more than 60 publicly-traded healthcare companies.Through this experience I met Vitality Biopharma’s Chairman and other Co-Founder, Dr. Avtar Dhillon. He is a physician and former venture capitalist who has deep healthcare and biotechnology experience. Dr. Dhillon currently acts as the Chairman of several publicly-traded healthcare companies, including Inovio Pharmaceuticals (NASDAQ:INO), which he led for many years as CEO and that is a prominent developer of DNA vaccines for cancer and infectious diseases. 

IMJ: Can you provide us a brief background on the company and what made you decide to focus on using cannabis as a key component of your planned drugs?

RB: Over the last several years, we developed a unique enzymatic biosynthesis platform at our company that enables the glycosylation of small molecule compounds, especially natural products. This platform was originally developed to modify the taste and create industrial quantities of stevia, a high-potency sweetener. This is a capability that very few other companies in the world have – even large pharmaceutical companies will generally create new drug compounds using chemical synthesis, rather than through enzymatic biosynthesis. 

In late 2015, we made a surprising discovery, which was that the enzymes we were using were far more promiscuous than anyone ever had realized before. So they were useful not only for improving the properties of stevia, but for improving the properties of many other compounds, including cannabinoids. As a result, we were able to file intellectual property and pursue patent protection that would extend through 2035 on a new class of cannabinoid pharmaceuticals known as cannabosides. 

We very quickly recognized the therapeutic potential of our compounds. Through oral delivery, cannaboside drug formulations can be selectively delivered to the gut or intestines. This enables large concentrations of cannabinoids to be delivered, in order to provide potent pain relief and anti-inflammatory effects, and to do this while reducing or avoiding entirely the drug’s psychoactivity. 

IMJ: Now that medical cannabis is being accepted by the medical community as a treatment for many ailments, there has been a surge of pharmaceutical companies entering the space and looking to bring cannabis based drugs to market. What makes Vitality BioPharma unique in terms the ailments you are focusing on? What are some of the current treatments for these ailments and how can patients benefit from your pipeline of drugs?

RB: There has been a surge of interest and acceptance of medical cannabis in the medical community, and for many, this has been driven largely by the success of non-psychoactive cannabidiol (CBD) for epilepsy. CBD isn’t psychoactive and it also has very obvious therapeutic effects - it’s now been shown to help reduce seizure frequency by more than 40% even in children with rare seizure disorders who previously failed all FDA-approved therapies. 

1 2 3 4
View single page >> |

Disclosure: This article is part of a new “UnderCovered” series of exclusive articles featuring companies with limited coverage. Authors are compensated by TalkMarkets for their time, and ...

more
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Alpha Stockman 2 years ago Member's comment

Any updates on $VBIO?

Robert T. Brooke 2 years ago Member's comment

Thanks for the interview, InvestInMJ. Happy to answer any readers' questions on #VitalityBiopharma. $VBIO

Alpha Stockman 2 years ago Member's comment

I'm in for some $VBIO

Alexa Graham 2 years ago Member's comment

Thanks for this.

Black Widow 2 years ago Member's comment

I think this is a booming area worth looking further into! #canabis

InvestInMJ 2 years ago Author's comment

We are still conducting further due diligence on the company and will be sharing our findings in our newsletter. At the moment, I do not have a position in the company.

Anastasija Janevska 2 years ago Member's comment

InvestInMJ, how can we get a copy of your newsletter once you have more info? Thanks. $VBIO.

InvestInMJ 2 years ago Author's comment

You can visit our site at www.investinmj.com and sign up there for the newsletter.

Bill Johnson 2 years ago Member's comment

Definitely going to take a closer look at $VBIO, thanks.

Anastasija Janevska 2 years ago Member's comment

Very impressive InvestInMJ. So would you recommend picking up some shares of $VBIO? Did you purchase it?

Kurt Benson 2 years ago Member's comment

This company looks very promising. I have to admit, I haven't heard of #VitalityBiopharma before but will be doing more due diligence on the stock and will consider adding it to my portfolio. $VBIO.